FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4300690843> ?p ?o ?g. }

• W4300690843 abstract "Together with inactivated influenza vaccines (IIV), live attenuated influenza vaccines (LAIV) are an important tool to prevent influenza A virus (IAV) illnesses in patients. LAIVs present the advantages to have a needle-free administration and to trigger a mucosal immune response. LAIV is approved for healthy 2- to 49-year old individuals. However, due to its replicative nature and higher rate of adverse events at-risk populations are excluded from the benefits of this vaccine. Using targeted mutagenesis, we modified the nonstructural protein 1 of the currently licensed LAIV in order to impair its ability to bind the host cellular protein CPSF30 and thus its ability to inhibit host mRNA poly-adenylation. We characterized our optimized LAIV (optiLAIV) in three different mouse models mimicking healthy and high-risk patients. Using a neonatal mouse model, we show faster clearance of our optimized vaccine compared to the licensed LAIV. Despite lower replication, optiLAIV equally protected mice against homosubtypic and hetesubtypic influenza strain challenges. We confirmed the safer profile of optiLAIV in Stat1-/- mice (highly susceptible to viral infections) by showing no signs of morbidity compared to a 50% mortality rate observed following LAIV inoculation. Using a human nasal 3D tissue model, we showed an increased induction of ER stress-related genes following immunization with optiLAIV. Induction of ER stress was previously shown to improve antigen-specific immune responses and is proposed as the mechanism of action of the licensed adjuvant AS03. This study characterizes a safer LAIV candidate in two mouse models mimicking infants and severely immunocompromised patients and proposes a simple attenuation strategy that could broaden LAIV application and reduce influenza burden in high-risk populations. IMPORTANCE Live attenuated influenza vaccine (LAIV) is a needle-free, mucosal vaccine approved for healthy 2- to 49-year old individuals. Its replicative nature and higher rate of adverse events excludes at-risk populations. We propose a strategy to improve LAIV safety and explore the possibility to expand its applications in children under 2-year old and immunocompromised patients. Using a neonatal mouse model, we show faster clearance of our optimized vaccine (optiLAIV) compared to the licensed LAIV. Despite lower replication, optiLAIV equally protected mice against influenza virus challenges. We confirmed the safer profile of optiLAIV in Stat1-/- mice (highly susceptible to viral infections) by showing no signs of morbidity compared to a 50% mortality rate from LAIV. OptiLAIV could expand the applications of the current LAIV and help mitigate the burden of IAV in susceptible populations." @default.
• W4300690843 created "2022-10-04" @default.
• W4300690843 creator A5014110371 @default.
• W4300690843 creator A5029204917 @default.
• W4300690843 creator A5047507129 @default.
• W4300690843 creator A5076024353 @default.
• W4300690843 creator A5078496527 @default.
• W4300690843 creator A5090499045 @default.
• W4300690843 date "2022-10-26" @default.
• W4300690843 modified "2023-10-17" @default.
• W4300690843 title "Optimizing the Live Attenuated Influenza A Vaccine Backbone for High-Risk Patient Groups" @default.
• W4300690843 cites W1767389458 @default.
• W4300690843 cites W1782160735 @default.
• W4300690843 cites W1973077339 @default.
• W4300690843 cites W1990655291 @default.
• W4300690843 cites W1992479402 @default.
• W4300690843 cites W1992648900 @default.
• W4300690843 cites W1998392642 @default.
• W4300690843 cites W1999352184 @default.
• W4300690843 cites W2000195334 @default.
• W4300690843 cites W2024323589 @default.
• W4300690843 cites W2042878897 @default.
• W4300690843 cites W2046253858 @default.
• W4300690843 cites W2055349955 @default.
• W4300690843 cites W2056080643 @default.
• W4300690843 cites W2066612271 @default.
• W4300690843 cites W2072383590 @default.
• W4300690843 cites W2072466889 @default.
• W4300690843 cites W2074871097 @default.
• W4300690843 cites W2079806155 @default.
• W4300690843 cites W2083437974 @default.
• W4300690843 cites W2086679521 @default.
• W4300690843 cites W2091527885 @default.
• W4300690843 cites W2102847984 @default.
• W4300690843 cites W2110214166 @default.
• W4300690843 cites W2115612309 @default.
• W4300690843 cites W2129056107 @default.
• W4300690843 cites W2157269914 @default.
• W4300690843 cites W2161083011 @default.
• W4300690843 cites W2161291046 @default.
• W4300690843 cites W2162238305 @default.
• W4300690843 cites W2163068558 @default.
• W4300690843 cites W2172121343 @default.
• W4300690843 cites W2555837754 @default.
• W4300690843 cites W2586492029 @default.
• W4300690843 cites W2617564580 @default.
• W4300690843 cites W2629434480 @default.
• W4300690843 cites W2751501504 @default.
• W4300690843 cites W2756483320 @default.
• W4300690843 cites W2807566375 @default.
• W4300690843 cites W2811497936 @default.
• W4300690843 cites W2902072701 @default.
• W4300690843 cites W2918155239 @default.
• W4300690843 cites W2947934890 @default.
• W4300690843 cites W2951633986 @default.
• W4300690843 cites W2958523037 @default.
• W4300690843 cites W2974248066 @default.
• W4300690843 cites W2980004052 @default.
• W4300690843 cites W2981907242 @default.
• W4300690843 cites W2989731979 @default.
• W4300690843 cites W2991607777 @default.
• W4300690843 cites W3003549994 @default.
• W4300690843 cites W3007834947 @default.
• W4300690843 cites W3015172298 @default.
• W4300690843 cites W3021246181 @default.
• W4300690843 cites W3089264604 @default.
• W4300690843 cites W3111038302 @default.
• W4300690843 cites W3134620343 @default.
• W4300690843 cites W3135810880 @default.
• W4300690843 cites W3136843608 @default.
• W4300690843 cites W3138033747 @default.
• W4300690843 cites W3148324319 @default.
• W4300690843 cites W3157352317 @default.
• W4300690843 cites W3159759495 @default.
• W4300690843 cites W3187217032 @default.
• W4300690843 cites W3197489959 @default.
• W4300690843 cites W3212826891 @default.
• W4300690843 doi "https://doi.org/10.1128/jvi.00871-22" @default.
• W4300690843 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/36190240" @default.
• W4300690843 hasPublicationYear "2022" @default.
• W4300690843 type Work @default.
• W4300690843 citedByCount "1" @default.
• W4300690843 countsByYear W43006908432023 @default.
• W4300690843 crossrefType "journal-article" @default.
• W4300690843 hasAuthorship W4300690843A5014110371 @default.
• W4300690843 hasAuthorship W4300690843A5029204917 @default.
• W4300690843 hasAuthorship W4300690843A5047507129 @default.
• W4300690843 hasAuthorship W4300690843A5076024353 @default.
• W4300690843 hasAuthorship W4300690843A5078496527 @default.
• W4300690843 hasAuthorship W4300690843A5090499045 @default.
• W4300690843 hasBestOaLocation W43006908431 @default.
• W4300690843 hasConcept C126322002 @default.
• W4300690843 hasConcept C133239900 @default.
• W4300690843 hasConcept C159047783 @default.
• W4300690843 hasConcept C203014093 @default.
• W4300690843 hasConcept C22070199 @default.
• W4300690843 hasConcept C2522874641 @default.
• W4300690843 hasConcept C2777546802 @default.
• W4300690843 hasConcept C2777863537 @default.
• W4300690843 hasConcept C2779134260 @default.

• next